Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL), a multicenter study

IF 2.9 3区医学 Q3 GERIATRICS & GERONTOLOGY

Journal of geriatric oncology Pub Date : 2026-03-01 Epub Date: 2026-03-13 DOI:10.1016/j.jgo.2026.102880

P. Torka , J. Meeko Manzano , L. Chen , V. Iyengar , J. Chicola , D. Russler-Germain , V. Pizzuti , A. Major , Y. Sawalha , D. Wallace , N. Birrer , A. Bock , Y. Wang , J. Rhodes , J. Crombie , J. Alderuccio , P. Reidell , B. Heyman , C. Ujjani , H.-J. Cherng , S. Kambhampati Thiruvengadam

引用次数: 0

查看原文本刊更多论文

一项多中心研究：新诊断弥漫性大b细胞淋巴瘤（DLBCL）的老年人，前线polatuzumab的真实结局和虚弱的影响

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of geriatric oncology ONCOLOGY-GERIATRICS & GERONTOLOGY

CiteScore

5.30

自引率

10.00%

发文量

379

审稿时长

80 days

期刊介绍： The Journal of Geriatric Oncology is an international, multidisciplinary journal which is focused on advancing research in the treatment and survivorship issues of older adults with cancer, as well as literature relevant to education and policy development in geriatric oncology. The journal welcomes the submission of manuscripts in the following categories: • Original research articles • Review articles • Clinical trials • Education and training articles • Short communications • Perspectives • Meeting reports • Letters to the Editor.